Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943486 | 0.84 | NCF1 (0.59) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL9850350 | 0.80 | NCF1 (0.57) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL5943501 | 0.80 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2NCF1KDM4E | |
| SCHEMBL5943549 | 0.79 | GRIN1 (0.51) | NPC1RAB9ASMN1; SMN2NCF1KDM4E | |
| SCHEMBL5943504 | 0.78 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2KMT2ANCF1 | |
| SCHEMBL5943554 | 0.78 | MC5R (0.57) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL5943479 | 0.77 | NCF1 (0.59) | NPC1RAB9ASMN1; SMN2NCF1KDM4E | |
| SCHEMBL5943471 | 0.76 | USP30 (0.48) | NPC1RAB9ASMN1; SMN2KMT2ANCF1 | |
| SCHEMBL8358537 | 0.76 | KMT2A (0.59) | SIGMAR1KMT2A | |
| SCHEMBL9768701 | 0.76 | SIGMAR1 (0.86) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247439-A1 | Mchir antagonists | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| US-20060247439-A1 | Mchir antagonists | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247439-A1 | Mchir antagonists | MCHR1, HCRTR1, MC3R | SIGMAR1 52/4885NPC1 193/4885RAB9A 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.